ABOS - CIK 0001576885
Acumen Pharmaceuticals, Inc. (ABOS) reported net income of -$121.33M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$121.33M | -18.6% |
| FY 2024 | -$102.33M | -95.4% |
| FY 2023 | -$52.37M | -22.2% |
| FY 2022 | -$42.86M | +57.4% |
| FY 2021 | -$100.61M | -1273.5% |
| FY 2020 | -$7.33M | - |
Acumen Pharmaceuticals, Inc. (ABOS) reported net income of -$121.33M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Acumen Pharmaceuticals, Inc.'s net income declined from -$7.33M to -$121.33M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.